SURUNKALI YALLIG‘LANISH KASALLIKLARI FONIDA METABOLIK SINDROMNING YURAK-QON TOMIR ASORATLARI RIVOJLANISHIDAGI PROGNOSTIK AHAMIYATI.
Keywords:
Metabolik sindrom, surunkali yallig‘lanish kasalliklari, yurak-qon tomir asoratlari, revmatoid artrit, psoriaz, insulin rezistentligi, ateroskleroz, prognostik ahamiyat, yallig‘lanish sitokinlari, kardiovaskulyar xavfAbstract
Surunkali yallig‘lanish kasalliklari (revmatoid artrit, psoriaz, tizimli qizil yug‘irish va boshqalar) fonida metabolik sindrom (MS) yurak-qon tomir asoratlarining rivojlanishi va prognozida muhim rol o‘ynaydi. Ushbu maqolada MSning surunkali yallig‘lanish jarayonlari bilan bog‘liq mexanizmlari, tarqalishi, prognostik ahamiyati va yurak-qon tomir kasalliklari (YQTK) xavfini oshirishi tahlil qilinadi. Adabiyotlar sharhi va sintetik natijalarga ko‘ra, MS surunkali yallig‘lanish kasalliklarida 2 baravar yuqori YQTK xavfini va o‘lim darajasini oshiradi. Revmatoid artritda MS tarqalishi 32% ni tashkil etadi, bu bemorlarda insulin rezistentligi, endotelial disfunksiya va aterosklerozni kuchaytiradi. Psoriazda MS bilan bog‘liq yallig‘lanish sitokinlari (TNF-α, IL-6) yurak-qon tomir asoratlarini 1,5–2 baravar oshiradi. Prognostik jihatdan, MS komponentlari (giperglikemiya, dislipidemiya, abdominal semizlik) kasallik faolligi bilan bog‘liq bo‘lib, 5–10 yil ichida YQTK va o‘lim xavfini sezilarli darajada oshiradi. Maqola maqsadi – MSni erta aniqlash va davolash orqali surunkali yallig‘lanish kasalliklarida YQTK asoratlarini oldini olish strategiyalarini taklif etishdir. Tadqiqot natijalari shuni ko‘rsatadiki, MSni nazorat qilish bemorlarning hayot sifati va prognozini yaxshilaydi
References
1. Cai, W., Li, X., Chen, Y., Zhu, W., & Zhang, L. (2022). Prevalence of metabolic syndrome and its association with cardiovascular risk in patients with rheumatoid arthritis: A systematic review and meta-analysis. Frontiers in Medicine, 9, 856421. https://doi.org/10.3389/fmed.2022.856421
2. Li, X., Wang, Y., Yang, X., & Zhang, L. (2021). Impact of metabolic syndrome on cardiovascular outcomes and all-cause mortality: A meta-analysis. Frontiers in Cardiovascular Medicine, 8, 705349. https://doi.org/10.3389/fcvm.2021.705349
3. Lopez-Candales, A., Hernández Burgos, P. M., Hernandez-Suarez, D. F., & Harris, D. (2017). Linking chronic inflammation with cardiovascular disease: From mechanisms to prevention. Journal of Natural Science, 3(9), e341.
4. Paoletti, R., Bolego, C., Poli, A., & Cignarella, A. (2006). Metabolic syndrome, inflammation and atherosclerosis. Vascular Health and Risk Management, 2(2), 145–152. https://doi.org/10.2147/vhrm.2006.2.2.145
5. Hansson, G. K. (2005). Inflammation, atherosclerosis, and coronary artery disease. New England Journal of Medicine, 352(16), 1685–1695. https://doi.org/10.1056/NEJMra043430
6. Hotamisligil, G. S. (2017). Inflammation, metaflammation and immunometabolic disorders. Nature, 542(7640), 177–185. https://doi.org/10.1038/nature21363
7. Ridker, P. M. (2016). From C-reactive protein to interleukin-6 to interleukin-1: Moving upstream to identify novel targets for atheroprotection. Circulation Research, 118(1), 145–156. https://doi.org/10.1161/CIRCRESAHA.115.306656
8. Avina-Zubieta, J. A., Thomas, J., Sadatsafavi, M., Lehman, A. J., & Lacaille, D. (2012). Risk of incident cardiovascular events in patients with rheumatoid arthritis: A meta-analysis of observational studies. Annals of the Rheumatic Diseases, 71(9), 1524–1529. https://doi.org/10.1136/annrheumdis-2011-200726
9. Grundy, S. M. (2004). Metabolic syndrome: Connecting and reconciling cardiovascular and diabetes worlds. Journal of the American College of Cardiology, 44(5), 1093–1100. https://doi.org/10.1016/j.jacc.2004.06.038
